Search alternatives:
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
lower decrease » larger decrease (Expand Search), linear decrease (Expand Search), teer decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
lower decrease » larger decrease (Expand Search), linear decrease (Expand Search), teer decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
-
3721
-
3722
-
3723
-
3724
Chromatin accessibility analysis of perinatal Vps34-deficient Tregs.
Published 2025“…Relative (normalized to average control in each experiment) fold-change comparisons between genotypes in each cell type are shown in bold (<b>A</b>, <b>B</b>). Data are shown as mean ± s.e.m. (<b>A</b>, <b>B</b>). Two-tailed Student <i>t</i> test (<b>A</b>, <b>B</b>, <b>I</b>), Benjamini–Hochberg test (<b>C</b>), Wilcoxon rank-sum test (<b>G</b>), Fisher’s exact tes<i>t</i> (<b>H</b>), or binomial test (<b>J</b>); NS, not significant. …”
-
3725
-
3726
ELISA kit information.
Published 2025“…<i>PTGFR</i> and <i>JNK</i> mRNA levels, MMP9 and ADH7 protein levels increased significantly in AN-LSCs after 0.313 μg/mL travoprost treatment (p≤0.039), while NF-κB and ADH7 protein levels decreased significantly in LSCs using 0.313 μg/mL travoprost (p=0.039; p<0.001).…”
-
3727
CONSORT diagram.
Published 2024“…The overall proportion of patients who experienced any adverse events was 57.8% in the GDFT group and 70.1% in the conventional group (P = 0.038), of which the occurrence of pleural effusion was significantly lower in the GDFT group than in the conventional group (9.5% vs. 19.7%; P = 0.024). …”
-
3728
Raw data.
Published 2024“…The overall proportion of patients who experienced any adverse events was 57.8% in the GDFT group and 70.1% in the conventional group (P = 0.038), of which the occurrence of pleural effusion was significantly lower in the GDFT group than in the conventional group (9.5% vs. 19.7%; P = 0.024). …”
-
3729
Postoperative outcomes.
Published 2024“…The overall proportion of patients who experienced any adverse events was 57.8% in the GDFT group and 70.1% in the conventional group (P = 0.038), of which the occurrence of pleural effusion was significantly lower in the GDFT group than in the conventional group (9.5% vs. 19.7%; P = 0.024). …”
-
3730
Postoperative complications.
Published 2024“…The overall proportion of patients who experienced any adverse events was 57.8% in the GDFT group and 70.1% in the conventional group (P = 0.038), of which the occurrence of pleural effusion was significantly lower in the GDFT group than in the conventional group (9.5% vs. 19.7%; P = 0.024). …”
-
3731
Western blot antibody information.
Published 2025“…<i>PTGFR</i> and <i>JNK</i> mRNA levels, MMP9 and ADH7 protein levels increased significantly in AN-LSCs after 0.313 μg/mL travoprost treatment (p≤0.039), while NF-κB and ADH7 protein levels decreased significantly in LSCs using 0.313 μg/mL travoprost (p=0.039; p<0.001).…”
-
3732
Information on healthy and aniridia subjects.
Published 2025“…<i>PTGFR</i> and <i>JNK</i> mRNA levels, MMP9 and ADH7 protein levels increased significantly in AN-LSCs after 0.313 μg/mL travoprost treatment (p≤0.039), while NF-κB and ADH7 protein levels decreased significantly in LSCs using 0.313 μg/mL travoprost (p=0.039; p<0.001).…”
-
3733
qPCR primers information.
Published 2025“…<i>PTGFR</i> and <i>JNK</i> mRNA levels, MMP9 and ADH7 protein levels increased significantly in AN-LSCs after 0.313 μg/mL travoprost treatment (p≤0.039), while NF-κB and ADH7 protein levels decreased significantly in LSCs using 0.313 μg/mL travoprost (p=0.039; p<0.001).…”
-
3734
-
3735
-
3736
-
3737
-
3738
-
3739
-
3740